

GENOME THERAPEUTICS CORP

Form 8-K

January 09, 2004

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): January 9, 2004

---

## GENOME THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

Massachusetts  
(State or other

jurisdiction of incorporation)

0-10824  
(Commission File Number)

04-2297484  
(I.R.S. Employer

Identification Number)

100 Beaver Street

Waltham, Massachusetts 02453

(Address of principal executive offices, including zip code)

**(781) 398-2300**

**(Registrant's telephone number, including area code)**

---

ITEM 5. OTHER EVENTS

On January 9, 2004, Genome Therapeutics Corp. issued a press release announcing the sale of Genome Therapeutics pending patent applications relating to the organism *Streptococcus pneumoniae* to Aventis Pasteur, which is attached hereto as Exhibit 99.1.

Item 7. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits

99.1 Press Release issued by Genome Therapeutics Corp. on January 9, 2004.



EXHIBIT INDEX

**Exhibit Number**

---

**Description**

---

99.1

Press Release issued by Genome Therapeutics Corp. on January 9, 2004.